Drug | Tablet
Linagliptin 2.5 mg + Metformin hydrochloride 1000 mg (prolonged/extended-release may vary by pack; confirm pack label)
Type 2 diabetes mellitus (as an adjunct to diet and exercise) to improve glycaemic control in adults when metformin alone is inadequate or when already treated with linagliptin and metformin.
Linagliptin is a DPP-4 inhibitor that increases incretin levels, leading to glucose-dependent insulin release and reduced glucagon secretion. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption and improves insulin sensitivity, lowering blood glucose without causing significant hypoglycaemia when used alone.
Oral tablet. Take exactly as prescribed, usually twice daily with meals (or as directed) to reduce stomach upset. Swallow whole with water; do not crush/chew if the pack is extended-release; follow label instructions. Monitor blood glucose regularly.
Common side effects of Trajenta Duo 2.5/1000 Tablet may include:
Risk of lactic acidosis with metformin (rare but serious): higher risk in kidney impairment, dehydration, severe infection, shock, liver disease, heavy alcohol use, or hypoxia/heart failure—seek urgent care for fast breathing, severe weakness, abdominal pain, or drowsiness. Assess renal function before starting and periodically; dose adjustments/avoid in significant renal impairment as per prescribing info. Temporarily stop metformin around iodinated contrast procedures and major surgery as advised. Pancreatitis and severe joint pain have been reported with DPP-4 inhibitors—stop and consult doctor if severe abdominal pain occurs. Use caution in elderly, undernourished, or those with alcohol use; monitor B12 with long-term use.
